FindTrial
Sign In

Comparative Clinical Study To Evaluate The Effect of Sarpagandha Ghana Vati and Kusmanda Rasayan After Medical Purgation in Management of Hypertension.

Comparative Clinical Study To Evaluate The Efficacy of Sarpagandha Ghana Vati and Kusmanda Rasayan After Virechana in Management of Vyanabala Vaishamya (Essential Hypertension)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/039948
Enrollment
100
Registered
2022-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Systolic blood pressure >140 mm Hg Diastolic blood pressure >90 mm Hg Fit for Purgation therapy Willing to consent

Exclusion criteria

Exclusion criteria: Systolic >180 mm Hg, Diastolic >100 mm Hg Secondary Hypertension (CKD, Endocrine disorder, Type I , Type II diabetic ,pregnancy induced hypertension Age below 21 and above 70 Unfit for virechana Hypersensitivity to trail drug

Design outcomes

Secondary

MeasureTime frame
Change in quality of life SF-36 quality of life.Timepoint: 106 days;Change in symptoms of Vyanabala Vaishamya (Essential Hypertension)Timepoint: 106 days—

Primary

MeasureTime frame
To evaluate and to compare the therapeutic effect of Sarpagandha Ghana Vati and Kushmanda Rasayana in the management of Vyanabala Vaishamya(Essential Hypertension).Timepoint: 106 days—

Countries

India

Contacts

Public ContactDr Gupteswar Mishra

All India Institute of Ayurveda

jonahdr@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026